Life and Health Today Weekly: Oura's IPO filing reveals what the ring does not yet do
Issue of 14 September 2026
What happened last week.
- Biohacking Oura's IPO filing reveals what the ring does not yet do
Oura filed to go public with $500 million in 2024 revenue and ambitions to detect illness and track blood glucose. Its own SEC filing says none of that is FDA-cleared as a diagnostic today. Here is what the documents actually show.
- Longevity NeuroSense splits its ALS drug trial into three to outrun the disease
NeuroSense Therapeutics is replacing a single large confirmatory trial for its ALS candidate PrimeC with three shorter, narrower studies, betting the redesign will get results faster than patients typically survive. The FDA has not yet approved the new pivotal trial design. No efficacy verdict exists yet: this is a story about trial strategy, not a treatment that has been shown to work.
- Longevity Durham startup raises $1.3m to screen longevity drugs in living worms
Magnitude Biosciences, a Durham University spinout, has secured $1.3 million to scale a platform that tests drug candidates in living C. elegans worms rather than isolated cells. The worm's short lifespan makes it unusually useful for ageing research, but the platform has not yet been tested in humans or shown to predict clinical outcomes.
- Longevity Naked mole rats may shuttle fat out of brain cells to avoid damage, mouse study finds
A study published in GeroScience compared how lipid droplets, tiny fat-storage structures inside cells, behave in the brains of naked mole rats and ordinary mice as both animals age. The findings hint at a cellular housekeeping mechanism that may help explain why naked mole rats live far longer and resist neurodegeneration. The work was done entirely in animals; nothing has been tested in people.
- Longevity A theoretical model links circadian collapse to neuronal DNA repair failure in aging
Researchers writing in GeroScience propose that a protein called TyrRS acts as a daily scheduler of DNA repair in neurons, and that its rhythm breaks down with age. The paper is a theoretical model, not a clinical trial, and its core predictions have not yet been tested in humans or animals. If the framework holds, it would reframe neurodegeneration as a timing failure rather than a capacity failure.
- Longevity Eating more eggs and peanuts in pregnancy did not cut babies' allergy risk
A randomised trial of 2,137 pregnant women found that doubling down on eggs and peanuts during pregnancy and breastfeeding made no difference to whether infants developed allergies to those foods by age one. The finding, published in the New England Journal of Medicine, closes one door while pointing firmly toward a strategy that does have evidence behind it: introducing those foods to babies early.
- Performance Black and green rice broke down more slowly in lab digestion tests
Researchers at Hokkaido University found that black and green Japanese rice contained unusual fat molecules not previously detected in rice, and that their starch broke down more slowly in laboratory simulations of digestion than ordinary white rice. The work, published in Food Research International, was done in a lab, not in people, and the health implications remain to be tested in human trials.
- Biohacking A child's blink rate tracks cognitive flexibility and prefrontal brain activity
In 113 preschoolers, researchers found that how often a child blinks spontaneously predicts how well they can switch mental rules, and maps directly onto activity in a specific region of the prefrontal cortex. The measurement requires nothing more than a video camera. The finding is associational, not causal, and has not yet been tested in clinical populations.
- Biohacking Pufferfish taste receptor solves a structural puzzle about how flavor is sensed
A University of Osaka team has mapped the first 3D crystal structure of an umami taste receptor from pufferfish, finding a molecular mechanism that lets it detect both savory and sweet amino acids. The discovery, published in PNAS, is structural biology in fish, not a human clinical finding, but it opens a concrete path toward engineering new flavor compounds. Here is what the science actually shows.
- Biohacking Mouse study maps the brain circuit that drives pregnancy food cravings
A team led by researchers at LSU's Pennington Biomedical Research Center has identified a specific neural pathway that appears to drive intense food cravings during pregnancy, in mice. The mechanism involves a potassium channel that quiets serotonin neurons and releases the brain's reward system. The findings are preclinical, but they point toward a biological explanation for something that has long been dismissed as a quirk.
- Longevity Why Americans Keep Buying Treatments That Do Not Work
A physician and author who studies medical fads tells MedPage Today that the answer is not stupidity but something more human: nobody wants to die. With social media amplifying unproven claims and regulatory guardrails weakening, the pattern that gave us snake oil is accelerating, not fading.
- Longevity Blocking growth hormone receptors in middle-aged mice extended lifespan by under 10%
A new mouse study found that disabling growth hormone receptors at the equivalent of midlife still lengthened lifespan, but only modestly, and the effect was smaller in females. The researchers themselves call the growth hormone pathway a promising target for ageing therapies, but the history of this research line suggests caution about what it might mean for people.